Clinical Trials
15 trialsNCT04302025 2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2 Recruiting
NCT04589845 2026-05-08
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06563999 2026-04-21
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT07419932 2026-02-19
NeoLATC
Fujian Medical University
Recruiting
NCT07418879 2026-02-18
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
Fudan University
Phase NA Not yet recruiting
NCT06195228 2025-08-14
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
Phase 4 Recruiting
NCT07010393 2025-06-08
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Phase 4 Not yet recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT05525858 2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
NCT04632992 2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2 Completed
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04204928 2021-08-13
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Blueprint Medicines Corporation
Approved for marketing